Tipsheet
What matters at India’s listed companies
Healthcare · Micro cap

Kerala Ayurveda targets ₹200 cr revenue by FY27

The nano-cap firm aims for 38% growth, banking on a 130% surge in e-products and a path to operating breakeven by January 2027.


Mkt cap₹274 cr
ROE0.00%
Debt / eq.6.95
₹200 cr FY27 revenue guidance, representing 38% growth over FY26.

What's new

  • Management targets ₹200 cr revenue for FY27.
  • Operating breakeven is set for January 2027.
  • Standalone revenue crossed ₹100 cr for the first time in FY26.

Why this matters

The guidance is ambitious for a company with a market cap of ₹275 cr. Achieving this target would mean generating revenue equivalent to 73% of its current market valuation, making the execution of its e-product and health services strategy the primary test for investors.

What we're watching

  • Progress on the delayed capital funding closure.
  • Quarterly updates on the 130% e-product growth target.
  • Cost-control measures as the company nears the January 2027 breakeven goal.

The full read

Kerala Ayurveda is setting a high bar for its ₹275 crore market cap. Management has issued FY27 revenue guidance of ₹200 crore, a 38% jump over the ₹145.4 crore reported in FY26. The company is betting on a 130% surge in its global e-product business and a 45% expansion in health services to get there. It also plans to hit operating breakeven by January 2027. While the standalone business recently crossed the ₹100 crore revenue threshold for the first time, the scale of this new target is significant—it represents roughly 73% of the company's current total market value. A delay in capital funding closure adds a layer of friction to these plans. Investors now have a concrete framework to track, but the gap between current operations and the ₹200 crore target is wide. The next few quarters will determine if this growth is realistic or merely aspirational.

Questions answered

What is the primary driver behind the FY27 revenue target?
The company expects growth to come from a 130% expansion in its global e-product business and a 45% increase in health services.
How does the FY27 guidance compare to recent performance?
The company reported total revenue of ₹145.4 cr in FY26, with standalone revenue crossing the ₹100 cr mark for the first time.
When does Kerala Ayurveda expect to reach operating breakeven?
The company targets operating breakeven by January 2027, relying on revenue scale-up and cost-reduction measures.
Are there any risks to the current growth plan?
The filing notes a delay in the closure of capital funding, which remains a key variable for the company's financial trajectory.
Mentioned: Kerala Ayurveda Ltd · Ayurvedagram
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.